Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone vs Combination Therapy in Stage I Membranous Nephropathy
NCT03466801Terminated
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisone in idiopathic membranous nephropathy (IMN) (2 arms). Primary endpoint: Nephrotic syndrome remission (complete and partial) at 12 months. Started Mar 2018; status: terminated.
02
Drugs
prednisone
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT03466801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466801.